Pathway to osteoporosis treatment: Patient perspectives

Bone ◽  
2009 ◽  
Vol 44 ◽  
pp. S90
Author(s):  
R. Sujic ◽  
D.E. Beaton ◽  
V. Elliot-Gibson ◽  
E. Bogoch
Keyword(s):  
Osteoporosis Treatment ◽  
Patient Perspectives ◽  
Treatment Patient

Do patients care who is paying for their ovarian cancer treatment? Patient perspectives on value-based assessments

2018 ◽  
Vol 149 ◽  
pp. 124
Author(s):  
J.R. Foote ◽  
A. Alvarez-Secord ◽  
M.I. Liang ◽  
J.A. Ehrisman ◽  
M. Wu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Treatment ◽  
Patient Perspectives ◽  
Treatment Patient

Travelling for radiation cancer treatment: Patient perspectives

2003 ◽  
Vol 12 (7) ◽  
pp. 664-674 ◽  
Author(s):  
Margaret I. Fitch ◽  
Ross E. Gray ◽  
Tom McGowan ◽  
Ian Brunskill ◽  
Shawn Steggles ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Patient Perspectives ◽  
Treatment Patient

scholarly journals The Hybrid Aesthetic Functional (HAF) Appliance: A Less Visible Proposal for Functional Orthodontics

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Christos Livas
Keyword(s):  
Age Groups ◽  
Patient Perspectives ◽  
Design Development ◽  
Orthodontic Appliance ◽  
Early Application ◽  
Thermoplastic Material ◽  
Treatment Patient ◽  
Class Ii Treatment ◽  
Functional Orthodontics ◽  
Technical Considerations

In modern orthodontics, aesthetics appear to have a decisive influence on orthodontic appliance preferences and acceptability. This paper reports the early application of a newly emerged functional device with enhanced aesthetics in a Class II treatment. Patient perspectives and technical considerations are discussed along with recommendations for further design development. It can be assumed that the use of thermoplastic material-based appliances may meet both the therapeutic and aesthetic demands of young age groups.

scholarly journals Premature Discharge from Methadone Treatment: Patient Perspectives

2009 ◽  
Vol 41 (3) ◽  
pp. 285-296 ◽  
Author(s):  
Heather Schacht Reisinger ◽  
Robert P. Schwartz ◽  
Shannon Gwin Mitchell ◽  
James A. Peterson ◽  
Sharon M. Kelly ◽  
...  
Keyword(s):  
Methadone Treatment ◽  
Patient Perspectives ◽  
Treatment Patient ◽  
Premature Discharge

Rationale, baseline characteristics and methodology of the non-interventional VIVA study in postmenopausal osteoporosis

2014 ◽  
Vol 23 (01) ◽  
pp. 49-55
Author(s):  
L. C. Hofbauer ◽  
D. Felsenberg ◽  
M. Amling ◽  
A. Kurth ◽  
P. Hadji
Keyword(s):  
Quality Of Life ◽  
Postmenopausal Osteoporosis ◽  
Primary Outcome ◽  
Osteoporosis Treatment ◽  
Secondary Outcome ◽  
Matched Pairs ◽  
Fracture History ◽  
Baseline Characteristics ◽  
Study Inclusion

SummaryIt is important to understand compliance and persistence with medication use in the clinical practice of osteoporosis treatment. The purpose of this work is to describe the “intravenous ibandronate versus oral alendronate” (VIVA) study, a non-interventional trial to assess the compliance and persistence of osteopenic postmenopausal women with treatment via weekly oral alendronate or intravenous ibandronate (Bonviva®) every three months.4477 patients receiving ibandronate 3 mg i. v. quarterly and 1491 patients receiving alendronate 70 mg orally weekly were included in the study. Matched pairs of 901 subjects in each group were also generated. Matching was performed on the basis of age, body mass index, fracture history at study inclusion, prior treatment with bisphosphonates and the number of concomitant disorders. Secondary outcome measures of osteoporosis related fractures, mobility restriction and pain, analgesia, quality of life questionnaires as well as attitudes to medications were assessed. The primary outcome parameters of compliance and persistence will be tracked in these subjects.At baseline, the entire collectives differed significantly on body weight (less in ibandronate group), duration since osteo - porosis diagnosis (longer in ibandronate), and incidence of prior osteoporotic fracture (higher in ibandronate group). The matched-pairs differed only on mobility restriction and quality of life (both worse in ibandronate group).The results from the VIVA study trial will provide scientific rationale for clinical recommendations in the pharmacological treatment of postmenopausal osteoporosis.

Sign in / Sign up

Export Citation Format

Share Document